Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435759 | 0.81 | KDR (0.56) | KDR | |
| SCHEMBL5245642 | 0.80 | PTPN1 (0.38) | PTPN1KDRAURKAAURKBNR4A1 | |
| SCHEMBL2435235 | 0.77 | PTPN1 (0.48) | PTPN1KDRNR4A1NR4A2NR4A3 | |
| SCHEMBL2435108 | 0.76 | PTPN1 (0.49) | PTPN1KDRNR4A1NR4A2NR4A3 | |
| SCHEMBL28242286 | 0.73 | RORC (0.41) | PTPN1KDRNPSR1AURKBGSK3B | |
| SCHEMBL13148295 | 0.73 | TUBB4A (0.42) | KDRAURKAAURKBRPS6KB1NPC1 | |
| SCHEMBL14893885 | 0.70 | GSK3B (0.47) | NPSR1AURKARPS6KB1GSK3BDYRK1A | |
| SCHEMBL30781986 | 0.70 | ALDH1A1 (0.44) | NPSR1GSK3BDYRK1AMAP4K4KMT2A | |
| SCHEMBL29141782 | 0.70 | ALDH1A1 (0.44) | NPSR1GSK3BDYRK1AMAP4K4KMT2A | |
| SCHEMBL18814953 | 0.69 | L3MBTL1 (0.49) | KDRGSK3BDYRK1AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| EP-1945217-B1 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | disclosed |
| US-8026247-B2 | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | NOVARTIS AG | 2008-12-11 | — | — | US | disclosed |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-11-20 | — | — | US | disclosed |
| EP-1945217-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | Novartis AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1794149-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006059234-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | KDR, FLT4, FLT1 | PTPN1 2181/4885KDR 1/4885NPSR1 727/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | PTPN1 1642/4885KDR 826/4885NPSR1 4084/4885 |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | MAP3K20, MAP3K1, MAP3K19 | PTPN1 1745/4885KDR 888/4885NPSR1 4098/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | PTPN1 2181/4885KDR 1/4885NPSR1 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.